A randomized phase III trial comparing sorafenib plus best supportive care (BSC) versus BSC alone in Child-Pugh B patients (pts) with advanced hepatocellular carcinoma (HCC): The BOOST study.

Bruno Daniele, Federica Perrone, Ciro Gallo et al.|Journal of Clinical Oncology|2012

Cited by 4